| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, CCR | 8 | 2021 | 24 | 2.720 |
Why?
|
| Chemokines, CC | 10 | 2019 | 50 | 2.720 |
Why?
|
| Prostatic Neoplasms | 11 | 2019 | 794 | 2.240 |
Why?
|
| Receptors, Chemokine | 8 | 2016 | 68 | 1.810 |
Why?
|
| Neoplasm Invasiveness | 11 | 2016 | 247 | 1.700 |
Why?
|
| Cell Movement | 16 | 2019 | 545 | 1.690 |
Why?
|
| Apoptosis | 9 | 2019 | 1317 | 1.580 |
Why?
|
| Chemokines | 5 | 2017 | 89 | 1.120 |
Why?
|
| Cell Line, Tumor | 17 | 2019 | 2128 | 1.110 |
Why?
|
| Receptors, Virus | 2 | 2016 | 20 | 1.090 |
Why?
|
| Chemokines, CXC | 6 | 2016 | 35 | 1.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 82 | 1.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 781 | 1.070 |
Why?
|
| Colonic Neoplasms | 2 | 2018 | 181 | 1.050 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 756 | 0.960 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 303 | 0.920 |
Why?
|
| Metalloproteases | 3 | 2015 | 16 | 0.890 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 336 | 0.860 |
Why?
|
| Neutrophils | 3 | 2022 | 124 | 0.860 |
Why?
|
| Immunotherapy | 1 | 2022 | 91 | 0.810 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 211 | 0.770 |
Why?
|
| Breast Neoplasms | 5 | 2019 | 1426 | 0.740 |
Why?
|
| Receptors, Scavenger | 2 | 2016 | 13 | 0.700 |
Why?
|
| Receptors, CXCR5 | 4 | 2014 | 15 | 0.700 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 178 | 0.680 |
Why?
|
| Proanthocyanidins | 1 | 2018 | 3 | 0.670 |
Why?
|
| Cytokines | 7 | 2017 | 569 | 0.650 |
Why?
|
| Receptors, CXCR3 | 6 | 2016 | 30 | 0.650 |
Why?
|
| Quercetin | 1 | 2018 | 41 | 0.640 |
Why?
|
| Chemokine CXCL13 | 5 | 2014 | 18 | 0.620 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2018 | 146 | 0.610 |
Why?
|
| Receptors, CXCR4 | 3 | 2013 | 67 | 0.610 |
Why?
|
| Humans | 35 | 2022 | 34853 | 0.600 |
Why?
|
| Receptors, CCR6 | 1 | 2016 | 3 | 0.580 |
Why?
|
| Prostate | 4 | 2016 | 136 | 0.570 |
Why?
|
| Andrographis | 1 | 2016 | 4 | 0.560 |
Why?
|
| Receptors, CXCR | 1 | 2016 | 6 | 0.560 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2016 | 12 | 0.560 |
Why?
|
| Cytoskeleton | 1 | 2016 | 98 | 0.540 |
Why?
|
| Epithelial Cells | 3 | 2016 | 366 | 0.540 |
Why?
|
| Cell Adhesion | 3 | 2016 | 209 | 0.540 |
Why?
|
| Diterpenes | 1 | 2016 | 83 | 0.530 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 97 | 0.520 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 209 | 0.500 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 107 | 0.500 |
Why?
|
| Matrix Metalloproteinases | 5 | 2019 | 44 | 0.490 |
Why?
|
| Disease Progression | 5 | 2019 | 580 | 0.480 |
Why?
|
| Facial Neoplasms | 1 | 2013 | 6 | 0.470 |
Why?
|
| Cheek | 1 | 2013 | 14 | 0.470 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 15 | 0.470 |
Why?
|
| Cell Survival | 4 | 2018 | 818 | 0.450 |
Why?
|
| Prostatic Hyperplasia | 2 | 2009 | 33 | 0.440 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 63 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 245 | 0.430 |
Why?
|
| RNA, Messenger | 8 | 2019 | 1152 | 0.430 |
Why?
|
| Signal Transduction | 6 | 2021 | 1802 | 0.420 |
Why?
|
| Caspase 3 | 2 | 2010 | 194 | 0.420 |
Why?
|
| Tumor Cells, Cultured | 6 | 2016 | 480 | 0.400 |
Why?
|
| Etoposide | 1 | 2010 | 21 | 0.390 |
Why?
|
| Cisplatin | 1 | 2011 | 70 | 0.390 |
Why?
|
| Cell Proliferation | 8 | 2019 | 1149 | 0.390 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 89 | 0.380 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 6 | 2014 | 41 | 0.370 |
Why?
|
| Male | 16 | 2019 | 18870 | 0.370 |
Why?
|
| Integrins | 1 | 2009 | 49 | 0.350 |
Why?
|
| Caspase 9 | 1 | 2009 | 27 | 0.350 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2009 | 54 | 0.340 |
Why?
|
| Drug Synergism | 2 | 2019 | 171 | 0.330 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 239 | 0.330 |
Why?
|
| Streptococcus pneumoniae | 4 | 2014 | 28 | 0.320 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2019 | 33 | 0.310 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 605 | 0.300 |
Why?
|
| Flow Cytometry | 4 | 2016 | 392 | 0.290 |
Why?
|
| Colitis | 4 | 2008 | 64 | 0.280 |
Why?
|
| Plant Extracts | 2 | 2021 | 250 | 0.280 |
Why?
|
| Pneumococcal Infections | 4 | 2014 | 27 | 0.280 |
Why?
|
| Bacterial Proteins | 4 | 2014 | 520 | 0.280 |
Why?
|
| Chemokine CCL5 | 4 | 2011 | 38 | 0.270 |
Why?
|
| Prognosis | 3 | 2018 | 707 | 0.260 |
Why?
|
| Female | 22 | 2019 | 19873 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 984 | 0.260 |
Why?
|
| Immunoenzyme Techniques | 3 | 2016 | 105 | 0.250 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 269 | 0.250 |
Why?
|
| Membrane Proteins | 3 | 2019 | 486 | 0.250 |
Why?
|
| Immunity, Mucosal | 5 | 2008 | 45 | 0.240 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 600 | 0.230 |
Why?
|
| Immunologic Factors | 2 | 2022 | 44 | 0.230 |
Why?
|
| Chemokine CXCL10 | 3 | 2015 | 37 | 0.230 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2014 | 55 | 0.230 |
Why?
|
| Antigens, CD34 | 2 | 2015 | 18 | 0.230 |
Why?
|
| Mice | 17 | 2014 | 5668 | 0.220 |
Why?
|
| Saccharum | 1 | 2022 | 4 | 0.220 |
Why?
|
| Sorghum | 1 | 2022 | 4 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2010 | 445 | 0.220 |
Why?
|
| Interferon-gamma | 7 | 2014 | 235 | 0.210 |
Why?
|
| Momordica charantia | 1 | 2021 | 17 | 0.200 |
Why?
|
| Neoplasms | 1 | 2011 | 1033 | 0.200 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2011 | 18 | 0.200 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2019 | 7 | 0.180 |
Why?
|
| Anthraquinones | 1 | 2019 | 7 | 0.180 |
Why?
|
| Interleukin-10 | 4 | 2008 | 69 | 0.180 |
Why?
|
| Blotting, Western | 4 | 2016 | 834 | 0.170 |
Why?
|
| Fungal Proteins | 1 | 2019 | 130 | 0.170 |
Why?
|
| Fluorouracil | 1 | 2018 | 32 | 0.170 |
Why?
|
| Ovary | 1 | 2019 | 101 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2010 | 251 | 0.160 |
Why?
|
| Chemokine CXCL11 | 2 | 2016 | 7 | 0.160 |
Why?
|
| Mycobacterium avium subsp. paratuberculosis | 2 | 2008 | 6 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 282 | 0.150 |
Why?
|
| Killer Cells, Natural | 2 | 2008 | 86 | 0.150 |
Why?
|
| Animals | 17 | 2014 | 14307 | 0.150 |
Why?
|
| Epitope Mapping | 2 | 2014 | 31 | 0.150 |
Why?
|
| Models, Biological | 2 | 2017 | 642 | 0.150 |
Why?
|
| Membrane Transport Proteins | 2 | 2009 | 88 | 0.140 |
Why?
|
| Chemokine CCL20 | 1 | 2016 | 7 | 0.140 |
Why?
|
| NF-kappa B | 1 | 2019 | 306 | 0.140 |
Why?
|
| Cyclin B1 | 1 | 2016 | 16 | 0.140 |
Why?
|
| CDC2 Protein Kinase | 1 | 2016 | 17 | 0.140 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 24 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 859 | 0.140 |
Why?
|
| Cyclins | 1 | 2016 | 35 | 0.140 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 27 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 29 | 0.140 |
Why?
|
| Cell Growth Processes | 1 | 2015 | 41 | 0.130 |
Why?
|
| ADAM Proteins | 1 | 2015 | 15 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 58 | 0.130 |
Why?
|
| Heme | 1 | 2015 | 69 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 7 | 2014 | 649 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1056 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 121 | 0.130 |
Why?
|
| Antioxidants | 1 | 2018 | 386 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 164 | 0.130 |
Why?
|
| Stem Cells | 1 | 2015 | 132 | 0.130 |
Why?
|
| Malaria, Falciparum | 1 | 2015 | 81 | 0.130 |
Why?
|
| Histones | 1 | 2016 | 177 | 0.130 |
Why?
|
| Tissue Array Analysis | 2 | 2011 | 65 | 0.120 |
Why?
|
| Th1 Cells | 4 | 2008 | 87 | 0.120 |
Why?
|
| Immunodominant Epitopes | 1 | 2014 | 27 | 0.120 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1349 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 287 | 0.120 |
Why?
|
| Antibodies, Bacterial | 3 | 2008 | 107 | 0.120 |
Why?
|
| Hematuria | 1 | 2013 | 3 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 220 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2013 | 38 | 0.120 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 63 | 0.120 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 57 | 0.110 |
Why?
|
| Protein Subunits | 1 | 2013 | 85 | 0.110 |
Why?
|
| Phosphorylation | 1 | 2016 | 878 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2010 | 423 | 0.110 |
Why?
|
| Protein Binding | 4 | 2021 | 913 | 0.110 |
Why?
|
| Mice, Knockout | 7 | 2011 | 897 | 0.100 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 16 | 0.100 |
Why?
|
| Models, Immunological | 1 | 2011 | 20 | 0.100 |
Why?
|
| Epitopes | 1 | 2011 | 145 | 0.100 |
Why?
|
| Dendritic Cells | 3 | 2008 | 112 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2011 | 188 | 0.100 |
Why?
|
| Interleukin-6 | 2 | 2009 | 140 | 0.100 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 28 | 0.090 |
Why?
|
| Chlamydia muridarum | 2 | 2008 | 104 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2010 | 42 | 0.090 |
Why?
|
| Mice, Nude | 1 | 2010 | 323 | 0.090 |
Why?
|
| Peptides | 2 | 2010 | 308 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 160 | 0.090 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 13 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2009 | 45 | 0.090 |
Why?
|
| Mice, SCID | 1 | 2009 | 143 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2009 | 89 | 0.080 |
Why?
|
| Technology, Pharmaceutical | 1 | 2008 | 25 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 95 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2009 | 100 | 0.080 |
Why?
|
| Nasal Mucosa | 2 | 2004 | 29 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 242 | 0.080 |
Why?
|
| Paratuberculosis | 1 | 2007 | 3 | 0.080 |
Why?
|
| Antibodies | 1 | 2008 | 135 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 2 | 2004 | 106 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 182 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 21 | 0.070 |
Why?
|
| Chlamydia Infections | 1 | 2008 | 196 | 0.070 |
Why?
|
| Plasmodium yoelii | 1 | 2005 | 10 | 0.070 |
Why?
|
| Carrier State | 1 | 2006 | 32 | 0.070 |
Why?
|
| Cerebellum | 1 | 2005 | 69 | 0.070 |
Why?
|
| Proteins | 1 | 2008 | 352 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 341 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 1 | 2005 | 30 | 0.070 |
Why?
|
| Malaria | 1 | 2005 | 68 | 0.070 |
Why?
|
| Immunoglobulin G | 4 | 2008 | 232 | 0.060 |
Why?
|
| Chemokine CXCL12 | 1 | 2004 | 28 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2005 | 61 | 0.060 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2004 | 20 | 0.060 |
Why?
|
| Enterocolitis | 1 | 2003 | 2 | 0.060 |
Why?
|
| Adoptive Transfer | 1 | 2003 | 48 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2004 | 106 | 0.060 |
Why?
|
| Lymphocyte Activation | 3 | 2014 | 222 | 0.060 |
Why?
|
| Carbohydrates | 1 | 2022 | 28 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2014 | 29 | 0.050 |
Why?
|
| Biomass | 1 | 2022 | 50 | 0.050 |
Why?
|
| Oleanolic Acid | 1 | 2021 | 3 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 4 | 2011 | 1530 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 20 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 550 | 0.050 |
Why?
|
| Aged | 1 | 2013 | 6448 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 325 | 0.050 |
Why?
|
| Immunoglobulin A | 3 | 2008 | 58 | 0.050 |
Why?
|
| Antigens, Bacterial | 3 | 2007 | 129 | 0.050 |
Why?
|
| Spleen | 2 | 2014 | 192 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 271 | 0.050 |
Why?
|
| Binding Sites | 1 | 2021 | 597 | 0.050 |
Why?
|
| Ascomycota | 1 | 2019 | 15 | 0.050 |
Why?
|
| Phenotype | 1 | 2022 | 650 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 1124 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 1490 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 407 | 0.040 |
Why?
|
| Up-Regulation | 3 | 2005 | 490 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2019 | 467 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2008 | 1300 | 0.040 |
Why?
|
| Antibody Formation | 2 | 2008 | 73 | 0.040 |
Why?
|
| Immunity, Cellular | 2 | 2008 | 68 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 2 | 2008 | 14 | 0.040 |
Why?
|
| Receptors, CCR5 | 2 | 2006 | 59 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2007 | 84 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2007 | 57 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2014 | 19 | 0.030 |
Why?
|
| Ligands | 2 | 2007 | 317 | 0.030 |
Why?
|
| Ovalbumin | 2 | 2004 | 43 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 28 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2004 | 75 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 96 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2014 | 67 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 172 | 0.030 |
Why?
|
| Receptor, PAR-1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Thrombin | 1 | 2013 | 24 | 0.030 |
Why?
|
| Cell Division | 2 | 2005 | 296 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 30 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2013 | 44 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2013 | 121 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 968 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 1289 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2015 | 1318 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2006 | 1442 | 0.030 |
Why?
|
| Chemokine CXCL5 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 751 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2010 | 12 | 0.020 |
Why?
|
| GTPase-Activating Proteins | 1 | 2010 | 26 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2010 | 103 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 117 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 901 | 0.020 |
Why?
|
| Absorption | 1 | 2008 | 22 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2008 | 5 | 0.020 |
Why?
|
| Drug Stability | 1 | 2008 | 110 | 0.020 |
Why?
|
| Child | 1 | 2015 | 2875 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2008 | 75 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 212 | 0.020 |
Why?
|
| Liposomes | 1 | 2008 | 107 | 0.020 |
Why?
|
| Particle Size | 1 | 2008 | 200 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 57 | 0.020 |
Why?
|
| Cell Separation | 1 | 2008 | 91 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 19 | 0.020 |
Why?
|
| Polymers | 1 | 2008 | 117 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2008 | 121 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 150 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 85 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 120 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2006 | 57 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 115 | 0.020 |
Why?
|
| Receptors, CCR1 | 1 | 2005 | 8 | 0.020 |
Why?
|
| Receptors, CCR3 | 1 | 2005 | 10 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 92 | 0.020 |
Why?
|
| DNA Primers | 1 | 2005 | 269 | 0.020 |
Why?
|
| Chemokine CCL1 | 1 | 2004 | 2 | 0.020 |
Why?
|
| Adhesins, Bacterial | 1 | 2005 | 18 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 5035 | 0.020 |
Why?
|
| Chemokine CXCL6 | 1 | 2004 | 2 | 0.020 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2004 | 16 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2004 | 39 | 0.020 |
Why?
|
| Chlamydia trachomatis | 1 | 2005 | 66 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 298 | 0.020 |
Why?
|
| Leukocytes | 1 | 2004 | 68 | 0.020 |
Why?
|
| Species Specificity | 1 | 2004 | 233 | 0.020 |
Why?
|
| Reaction Time | 1 | 2004 | 130 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2004 | 116 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2008 | 294 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2004 | 135 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2003 | 18 | 0.010 |
Why?
|
| Immune Sera | 1 | 2003 | 59 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 181 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 58 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 2003 | 19 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 197 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 278 | 0.010 |
Why?
|
| Crohn Disease | 1 | 2003 | 55 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2003 | 156 | 0.010 |
Why?
|
| Feces | 1 | 2003 | 110 | 0.010 |
Why?
|
| Proteomics | 1 | 2005 | 302 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 608 | 0.010 |
Why?
|
| Weight Loss | 1 | 2003 | 124 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1681 | 0.010 |
Why?
|
| Adult | 1 | 2008 | 11034 | 0.010 |
Why?
|